dilated-cardiomyopathy-therapeutics-market

Dilated Cardiomyopathy Therapeutics Market By Treatment (Drug Class, Implantable Device) - Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

11 Nov 2018 Format PDF icon PPT icon XLS icon Request Sample

Industry Outlook

The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2030 from US$ xx Mn in 2021 featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2023 to 2030. As per the latest research citings of World Health Organization (WHO), annually 17.9 million people die throughout the globe from cardiovascular diseases which is equivalent o 31% of all global deaths. Factors responsible for congestive heart failure are sedentary lifestyle, obesity, unhealthy lifestyle and congenital heart complications.

Pharmaceuticals companies are striving earnestly to manufacture drugs with least possible side effects and desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma) and ixCELL-DCM (Vericel Corporation).

"Excellent clinical outcomes and satisfactory patient compliance makes drug class the most viable treatment option for dilated cardiomyopathy"

In the current scenario drug class are reigning the treatment segment for dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of drug class are increasing number of patients diagnosed with congestive heart failure. Moreover excellent clinical outcomes and satisfactory patient compliance make drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin converting enzyme inhibitors (ACE inhibitors) are considered as first line of drug therapy due to its positive clinical effects such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients that do not tolerate ACE inhibitors. They help to regulate the blood flow by widening of blood vessels and reducing the fluid in lungs and kidneys. Beta blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to inability of the weakened left ventricular muscles to pump the blood. Implantable devices are gaining traction owing to the side effects associated with drug class and long term benefit provided by devices such as heart pumps, biventricular pacemakers and implantable cardioveter-defibrillators.

"Rising prevalence of congestive heart failure drive the dilated cardiomyopathy therapeutics market growth in North America"

North America is currently leading the geography segment for dilated cardiomyopathy therapeutics market owing to factors such as rising prevalence of congestive heart failure. According to the facts presented by Center for Disease Control and Prevention (CDC) in United States approximately 610,000 people die of heart disease annually. Existence of well-developed healthcare infrastructure and affordable reimbursement scenario drive the dilated cardiomyopathy market growth in North America. As per the latest research citings of European Heart Network (EHN) every year 3.9 million people die in Europe amounting to 45% of all deaths caused in the region. Domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc and t2cure GmbH etc., propel the market growth in European Union region.  Asia Pacific will register outstanding growth during the forecast period on account of rising prevalence of congenital heart diseases, favorable regulatory scenario and growing medical tourism due to affordable treatment cost. Latin America and Middle East & Africa serve as a potential market to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players proving treatment option for dilated cardiomyopathy.

Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH, Teva Pharmaceutical Industries, ZensunSci & Tech.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Dilated Cardiomyopathy Therapeutics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Dilated Cardiomyopathy Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Treatment
  • Drug Class
    •     Angiotensin II Receptor Blockers
    •     Angiotensin-Converting Enzyme (ACE) Inhibitors
    •     Beta Blockers
    •     Anticoagulants
    •     Digitalis
    •     Diuretics
  • Implantable Device
    •     Heart Pumps
    •     Biventricular Pacemakers
    •     Implantable Cardioverter-Defibrillators

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Dilated Cardiomyopathy Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Dilated Cardiomyopathy Therapeutics market?
  • Which is the largest regional market for Dilated Cardiomyopathy Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Dilated Cardiomyopathy Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Dilated Cardiomyopathy Therapeutics market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports